RMC No. 2-2019 implements VAT exemption for FDA-listed diabetes, high-cholesterol, and hypertension drugs, with EDPMS and price reporting rules.

Drug manufacturers, distributors, wholesalers, retailers, hospital pharmacies, and other FDA-licensed establishments must apply VAT exemption only to qualified diabetes, high-cholesterol, and hypertension medicines in final form, and only when those medicines are included in the FDA-published list of VAT-exempt drugs. Sales outside that list remain subject to VAT, while importation of the same drugs remains subject to VAT under Section 107 of the National Internal Revenue Code.

What RMC No. 2-2019 Changed

RMC No. 2-2019 published Joint Administrative Order No. 2-2018, which implements the VAT exemption under Section 109(AA) of the National Internal Revenue Code of 1997, as amended by Republic Act No. 10963, otherwise known as the TRAIN Law. The key rule is straightforward but commercially significant: beginning January 1, 2019, the sale of drugs prescribed for diabetes, high cholesterol, and hypertension is exempt from VAT, provided the drugs are covered by the official FDA list.

The exemption applies to sales by manufacturers, distributors, wholesalers, and retailers of the covered drugs in their final form. This is important for pharmaceutical companies, drugstores, hospitals, clinics with pharmacies, wholesalers, and corporate taxpayers in the medicine supply chain because the VAT treatment depends not merely on the disease category, but on whether the specific drug is included in the List of VAT-exempt Diabetes, High-Cholesterol and Hypertension Drugs published by the FDA.

The issuance also clarifies a major limitation: the importation of these drugs is still subject to VAT under Section 107 of the National Internal Revenue Code. In other words, the VAT exemption under RMC No. 2-2019 is focused on the sale of qualified drugs, not their importation. Businesses involved in importing medicines should not assume that the exemption automatically removes VAT at the importation stage.

Who Is Affected by the VAT Exemption on Medicines

The affected taxpayers are manufacturers, distributors, wholesalers, and retailers selling drugs prescribed for diabetes, high cholesterol, and hypertension in final form. Retail drugstores, hospital pharmacies, pharmaceutical distributors, wholesale medicine suppliers, and FDA-licensed establishments should review their product lists, pricing systems, invoice templates, and point-of-sale configurations to ensure the correct VAT treatment.

The rule is also relevant to CFOs, corporate accountants, tax managers, and compliance officers handling VAT returns, sales invoicing, inventory classification, and price monitoring submissions. For taxpayers searching for BIR VAT exemption medicines Philippines, VAT exempt diabetes drugs, VAT exempt hypertension medicines, VAT exempt high cholesterol drugs, or RMC 2-2019 VAT exemption, the operational takeaway is that classification must be product-specific and list-based.

The issuance expressly states that the VAT exemption granted to senior citizens under Republic Act No. 7432 and to persons with disabilities under Republic Act No. 7277 is not covered by this issuance. Those senior citizen and PWD VAT exemptions remain governed by their own laws and implementing rules. RMC No. 2-2019 deals specifically with the TRAIN Law VAT exemption for certain drugs prescribed for diabetes, high cholesterol, and hypertension.

Key Compliance Requirements and Deadlines

The first compliance requirement is list verification. The sale of drugs not included in the FDA-published List of VAT-exempt Diabetes, High-Cholesterol and Hypertension Drugs is not exempt from VAT. Businesses should therefore treat the FDA list as the controlling reference for product classification and must avoid applying VAT exemption based only on a generic description, internal product category, or customer representation.

The second compliance requirement is EDPMS reporting. In addition to the current list of drugs monitored by the Department of Health through the Electronic Drug Price Monitoring System, all drugs included in the VAT exemption list must also be reported by manufacturers, distributors, and retailers in the EDPMS in accordance with existing DOH guidelines. This makes the VAT exemption not merely a tax coding issue, but also a price monitoring and regulatory reporting issue.

The third compliance requirement is submission of a sworn statement to the Department of Health. Within 60 days from the effectivity of the guidelines, all manufacturers, distributors, and retailers must submit a sworn statement containing the wholesale price, suggested retail price, and actual retail price prior to and after the effectivity of the guidelines. Since the guidelines took effect on January 1, 2019, affected businesses were required to act within the 60-day period reckoned from that effectivity date.

The sworn statement requirement is particularly important because it captures pricing before and after the VAT exemption. This allows government agencies to monitor whether the VAT exemption is reflected in medicine pricing and patient access. Accounting, tax, regulatory, and commercial teams should therefore coordinate so that wholesale price, suggested retail price, and actual retail price data are consistent, supportable, and properly documented.

FDA List, Quarterly Updates, and Posting Requirements

The FDA is tasked to identify the drugs specifically prescribed for the treatment and/or prevention of diabetes, high cholesterol, and hypertension that will be included in the VAT-exempt list. The FDA must also regularly update the list when drugs are registered or de-registered, and provide the updated list to the DOH and BIR thirty (30) days before the beginning of every quarter.

The FDA is also required to require the posting of the List of VAT-exempt Diabetes, High-Cholesterol and Hypertension Drugs conspicuously in the place of business of manufacturers, wholesalers, distributors, retailers of the VAT-exempt drugs, hospital pharmacies, and other FDA-licensed establishments. This means affected establishments should not treat the list as an internal accounting reference only. The list must be made visible in the place of business when required.

For businesses, the practical issue is change management. A drug may become covered or removed depending on FDA registration or de-registration updates. Tax and accounting teams should not rely on a static list indefinitely. They should establish a process to check BIR and FDA updates before every quarter and update invoicing, POS, ERP, and product master data accordingly.

VAT Treatment: Sale Is Exempt, Importation Remains Taxable

RMC No. 2-2019 draws a clear distinction between sale and importation. The sale by manufacturers, distributors, wholesalers, and retailers of covered drugs in final form is exempt from VAT under Section 106 of the National Internal Revenue Code, as amended. However, the importation of the same drugs is subject to VAT under Section 107 of the same Code.

This distinction matters for landed cost, pricing, and VAT return preparation. Importers should not automatically remove VAT from import entries or assume that input VAT at importation disappears because downstream sales may be VAT-exempt. Businesses should examine the VAT consequences of importing, distributing, and retailing the covered medicines as separate taxable events.

Penalties for Non-Compliance

The issuance states that the applicable penalties under the National Internal Revenue Code of 1997, as amended, and other laws shall apply. It does not specify a separate schedule of penalties in the implementing guidelines. However, non-compliance may expose affected taxpayers to issues involving VAT invoicing, improper availment of exemption, incorrect VAT reporting, failure to comply with price monitoring rules, and other regulatory violations depending on the facts.

Because the BIR is tasked to address complaints on violation of invoicing requirements and other VAT-related issues in the availment of the exemption, businesses should treat invoice compliance as a priority. Applying VAT exemption to a non-listed drug, failing to properly reflect VAT treatment in sales documentation, or failing to support pricing information may create avoidable exposure during BIR review or regulatory inquiry.

Practical Steps for Businesses

First, identify all products sold by the business that are prescribed for diabetes, high cholesterol, and hypertension. Second, match each product against the FDA-published list of VAT-exempt drugs. Third, separate covered and non-covered products in the accounting system, point-of-sale system, and invoice issuance process. Fourth, verify whether EDPMS reporting obligations apply and ensure that required price information is submitted. Fifth, prepare and retain documentation showing wholesale price, suggested retail price, and actual retail price before and after January 1, 2019.

Businesses should also train accounting, sales, pharmacy, and compliance personnel on the narrow scope of the exemption. The tax-exempt treatment is not based solely on the customer, not based solely on the illness category, and not automatically available for all medicines used by diabetic, hypertensive, or high-cholesterol patients. The controlling operational question is whether the specific drug is in final form and included in the FDA list of VAT-exempt Diabetes, High-Cholesterol and Hypertension Drugs.

How Ablola, Saribong & Gueco Can Help

RMC No. 2-2019 affects both tax compliance and regulated pharmaceutical operations. For drugstores, distributors, manufacturers, hospital pharmacies, and healthcare-related businesses, the risk lies in misclassifying products, mishandling VAT invoices, failing to update systems when the FDA list changes, or overlooking EDPMS and sworn statement obligations.

Ablola, Saribong & Gueco assists businesses with BIR compliance, VAT advisory, tax documentation, regulatory review, and implementation of internal controls for Philippine tax issuances. If your company sells, distributes, imports, or retails medicines and needs guidance on VAT exemption, invoice treatment, FDA list monitoring, or BIR audit readiness, consult Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *